Labiotech.eu

News and Trends 4 Nov 2022

A new weapon against antibiotic-resistant bacteria?

Is edoxudine, an anti-herpes molecule discovered in the 60s, effective against Klebsiella pneumoniae, a common bacterium in hospitals? The excessive use of antibiotics has pushed bacteria to develop resistance mechanisms to treatment. Antibiotic resistance is now considered by the WHO as one of the greatest threats to health. The lack of treatment against multi-resistant bacteria […]

November 4, 2022 - 3 minutesmins - By Jim Cornall

Best in Biotech 4 Nov 2022

Get to know 15 of the best biotech companies in Paris

Paris may attract tourist masses, but it also attracts a lot of biotech enthusiasts. In this guide, we explore 15 interesting biotech companies in Paris. Paris is one of the biggest biotech clusters in Europe, with a wide range of applications being developed from drug discovery and medical devices to synthetic biology and green energy. […]

November 4, 2022 - 11 minutesmins - By Omnia Ibrahim

News and Trends 4 Nov 2022

Novadip Biosciences raises €40M for bone defect treatments

Novadip Biosciences has raised an additional €40 million ($39.2 million) in a series B equity round and non-dilutive funding. The clinical-stage biopharma company is developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. The funding will accelerate the clinical development of two of […]

November 4, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 4 Nov 2022

Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation

This week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation’s CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution […]

November 4, 2022

News and Trends 4 Nov 2022

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Two companies with sole rights to two CRISPR diagnostic methods in markets outside the U.S. and Greater China have signed a licensing agreement. Sherlock Biosciences announced today (November 3) that it has signed a deal with China-based Tolo Biotech which grants co-exclusive rights to the Cas12 and Cas13 method patents. As the only two companies […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Trial and new drug for Tourette Syndrome after $250M after funding round completed

A phase 3 clinical trial and the potential commercialization of a new class of drug for patients with Tourette Syndrome have been funded after an upsized and oversubscribed $250 million series D funding round. Emalex Biosciences announced the closing today (November 3) of the round that was led by Bain Capital Life Sciences with participation […]

November 3, 2022 - 3 minutesmins - By Liza Laws

In Depth 3 Nov 2022

What’s on the horizon for gene editing-based therapies?

Gene editing has come far in the past decade. However, the field is still finding its feet regarding challenges such as drug delivery, regulation and competition with first-generation gene therapies. Gene editing is a sizzling hot topic in the biotech industry, powered by advances in genetic tools such as CRISPR, TALENs and zinc-finger nucleases. Gene […]

November 3, 2022 - 8 minutesmins - By Jonathan Smith

Biocomposites Ltd shutterstock diabetic foot ulcer

News and Trends 3 Nov 2022

New method to treat diabetic foot ulcers revealed by Biocomposites Ltd

Diabetic foot infection costs the UK’s NHS around £900 million ($990 million) a year, bringing severe misery to patients. Usually, systemic antibiotics are routinely given to those with diabetes who are susceptible to infected foot ulcers. Unfortunately, effective treatment can be disrupted by complications by using this treatment due to allergic reactions, antibiotic-resistant organisms, the […]

November 3, 2022 - 3 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Positive results of cancer treatment to be presented at Boston conference

Results of a cancer treatment in the treatment of gynecologic and breast cancer are to be presented next week, November 8-12, at the Society for Immunotherapy of Cancer (SITC) conference in Boston. Alderaan Biotechnology is a preclinical biotech company that focuses on monoclonal antibody development. It will be making announcements about the most recent development […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Rapid test kits that can accurately identify infections related to respiratory syncytial virus (RSV), influenza and Covid-19 can deliver results in 15 minutes. UK-based Virax Biolabs, a biotech company focused on the prevention, detection and diagnosis of viral diseases announced today (November 3) the distribution of a tripe virus antigen rapid test kit has been […]

November 3, 2022 - 2 minutesmins - By Liza Laws

News and Trends 3 Nov 2022

Senescent cells as vaccines against cancer?

Cancer cells have a series of features that allow the immune system to identify and attack them. However, these same cells create an environment that blocks immune cells and protects the tumor. This means immune cells cannot reach the cancer cells to remove them. The scientific community has been working to increase the effectiveness of […]

November 3, 2022 - 5 minutesmins - By Jim Cornall

News and Trends 3 Nov 2022

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s syndrome. The international, randomized, double-blind, placebo-controlled, phase 2a study is designed to evaluate the efficacy and tolerance of the monoclonal antibody OSE-127/S95011 in primary Sjögren’s […]

November 3, 2022 - 2 minutesmins - By Jim Cornall

Knowledge hub

Categories

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

Approaches

Therapeutic areas

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

A new weapon against antibiotic-resistant bacteria?

Get to know 15 of the best biotech companies in Paris

Novadip Biosciences raises €40M for bone defect treatments

Beyond Biotech podcast 21: CanSinoBIO, HTID, Longevity Science Foundation

Companies with exclusive rights to CRISPR diagnostic methods sign agreement

Trial and new drug for Tourette Syndrome after $250M after funding round completed

What’s on the horizon for gene editing-based therapies?

New method to treat diabetic foot ulcers revealed by Biocomposites Ltd

Positive results of cancer treatment to be presented at Boston conference

Virax Biolabs introduces flu, Covid-19 and RSV rapid test kits

Senescent cells as vaccines against cancer?

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Subscribe to our newsletter to get the latest biotech news!

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Illuminating biotech in the City of Light: Inside Paris’s thriving ecosystem

ASCO 2025: key highlights in cancer therapeutics

New report: Artificial intelligence and the future of antibody discovery

Stem cell therapy: a potential cure for hearing loss?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!